Focus: Roche is a global integrated pharmaceutical and diagnostics company with 100,000 employees, founded in 1896 and headquartered in Basel, Switzerland (data shows Norway entry, likely headquarters notation error). Market leader in oncology, neuroscience, and immunology with strong small molecule and biologic capabilities.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Contracting — net -40 jobs in 30d
292 added, 332 removed. Active reduction in progress.
3 recent layoff filings (12 mo) — 346 affected
Source: state DOL filings via Big Local News
Strong career destination for pipeline-focused scientists and commercial professionals, but exposure to near-term patent cliffs requires careful timing of entry and role choice.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship monoclonal antibody therapy facing patent expiration; sustained revenue indicates strong clinical franchise but limited future growth.
Help build intelligence for Roche
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Roche's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Precision oncology workhorse with 10+ year patent exclusivity; positioned to defend market share against emerging ALK inhibitors.
CD20-directed biologic with broad autoimmune utility; patent protection extends beyond 2030 with label expansion potential.
Orphan-indication breakthrough with exceptional patent duration and expanding pediatric adoption; rare growth asset in SMA space.
Hedgehog antagonist facing imminent patent cliff in 2028; revenue retention depends on label expansions in glioblastoma.
95 discontinued, 23 duplicate formulations not shown
+17 more products with revenue data
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+13 more products
+2 more
Source: state DOL filings, aggregated via Big Local News
No recent warn or FDA warnings; two active drug shortages (clonazepam) are non-portfolio items with minimal company exposure.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo